Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	26.96	134.55	7.42	13.17	54.59	18.92
Cash & Short-Term Investments	111.62	134.55	7.42	13.17	54.59	18.92
Cash Growth	36.35%	1714.51%	-43.71%	-75.87%	188.52%	424.15%
Accounts Receivable	-	-	-	-	1.06	2.18
Other Receivables	-	0.61	0.14	1.92	3.74	2.21
Receivables	-	0.61	0.14	1.92	4.8	4.39
Inventory	-	-	-	0.02	0.04	0
Prepaid Expenses	2.14	3.71	0.84	1.29	2.37	2.66
Restricted Cash	0.09	0.02	0	0.02	0.05	0.04
Total Current Assets	113.85	138.89	8.4	16.42	61.85	26.01
Property, Plant & Equipment	0.54	1.21	1.97	2.41	2.7	1.61
Goodwill	10.5	10.5	10.5	14.41	14.41	14.41
Other Intangible Assets	-	-	-	-	0.04	1.59
Other Long-Term Assets	0.21	0.13	0.13	0.13	1.23	0.15
Total Assets	125.1	150.73	20.99	33.37	80.21	43.76
Accounts Payable	0.47	0.28	0.45	2.88	3.37	2.57
Accrued Expenses	6.77	5.22	1.76	10.51	14.29	8.86
Current Portion of Long-Term Debt	-	-	-	5.93	-	-
Current Portion of Leases	0.44	0.57	0.54	0.53	0.49	0.43
Current Unearned Revenue	-	-	-	0.09	-	-
Other Current Liabilities	0.29	0.89	1.87	2.17	1.74	3.36
Total Current Liabilities	7.97	6.96	4.62	22.11	19.89	15.23
Long-Term Debt	-	-	-	13.49	32.83	-
Long-Term Leases	0.12	0.35	1.37	1.71	2.02	1.04
Long-Term Deferred Tax Liabilities	0.3	0.27	0.16	0.14	0.11	0.09
Other Long-Term Liabilities	25.16	10.12	7.55	6.83	2.28	2.84
Total Liabilities	33.55	17.7	13.69	44.28	57.13	19.19
Common Stock	0.02	0.01	0	-	0.01	0.08
Additional Paid-In Capital	526.29	503.29	342.44	292.91	285.24	202.28
Retained Earnings	-434.8	-370.26	-335.13	-303.82	-262.17	-177.79
Comprehensive Income & Other	0.04	-	-	-	-	-
Total Common Equity	91.55	133.03	7.3	-10.92	23.08	24.56
Shareholders' Equity	91.55	133.03	7.3	-10.92	23.08	24.56
Total Liabilities & Equity	125.1	150.73	20.99	33.37	80.21	43.76
Total Debt	0.56	0.92	1.9	21.66	35.34	1.46
Net Cash (Debt)	111.06	133.63	5.51	-8.49	19.25	17.46
Net Cash Growth	38.44%	2324.31%	-	-	10.28%	645.41%
Net Cash Per Share	9.74	17.83	19.85	-216.49	531.87	684.21
Filing Date Shares Outstanding	18.13	10.67	1.03	0.06	0.04	0.56
Total Common Shares Outstanding	17.83	10.47	0.8	0.04	0.04	0.55
Working Capital	105.87	131.93	3.78	-5.7	41.96	10.78
Book Value Per Share	5.14	12.70	9.11	-277.78	589.35	44.33
Tangible Book Value	81.05	122.53	-3.2	-25.32	8.64	8.57
Tangible Book Value Per Share	4.55	11.70	-3.99	-644.47	220.48	15.46
Machinery	-	0.28	0.28	0.34	0.24	0.21
Leasehold Improvements	-	0.9	0.9	0.74	0.74	0.66

Updated Nov 6, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q